JP2015517477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517477A5 JP2015517477A5 JP2015510743A JP2015510743A JP2015517477A5 JP 2015517477 A5 JP2015517477 A5 JP 2015517477A5 JP 2015510743 A JP2015510743 A JP 2015510743A JP 2015510743 A JP2015510743 A JP 2015510743A JP 2015517477 A5 JP2015517477 A5 JP 2015517477A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- hexanoyl
- carboxy
- butanoyl
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 240
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 128
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 120
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 84
- -1 imidazopropionyl Chemical compound 0.000 claims 83
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 50
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 5
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 239000013067 intermediate product Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 230000003915 cell function Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- WLNMZODBWIWRGN-SSDOTTSWSA-N (2R)-2-amino-2-formyl-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C(=O)[C@](N)(CC1=CNC=N1)C(=O)O WLNMZODBWIWRGN-SSDOTTSWSA-N 0.000 claims 1
- OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims 1
- HSFOBLRKJTWQRO-ZCFIWIBFSA-N (2r)-2-amino-2-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@](O)(N)CC1=CN=CN1 HSFOBLRKJTWQRO-ZCFIWIBFSA-N 0.000 claims 1
- UWBZDVGFOHDWHA-NRFANRHFSA-N (2s)-2-(dimethylamino)-6-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](N(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UWBZDVGFOHDWHA-NRFANRHFSA-N 0.000 claims 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims 1
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 claims 1
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 claims 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims 1
- UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 claims 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims 1
- IINRZEIPFQHEAP-UHFFFAOYSA-N 1-aminocycloheptane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCCCC1 IINRZEIPFQHEAP-UHFFFAOYSA-N 0.000 claims 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 1
- PJSQECUPWDUIBT-UHFFFAOYSA-N 1-azaniumylcyclooctane-1-carboxylate Chemical compound OC(=O)C1(N)CCCCCCC1 PJSQECUPWDUIBT-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 0 CCC(N[C@@](CCC(NCCCC[C@@](C(NCCCC[C@@]1NCCC(CC[C@](C(*)=O)N*)CNC1=O)=O)N)=O)CO)=O Chemical compound CCC(N[C@@](CCC(NCCCC[C@@](C(NCCCC[C@@]1NCCC(CC[C@](C(*)=O)N*)CNC1=O)=O)N)=O)CO)=O 0.000 description 5
- LOHODVKOTZCMNI-URRMOVRVSA-N CCCCNC([C@H](CCCCNC(C(CO)NC(CNC(C(CO)NC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCOc(cc1)ccc1C(O)=O)=O)=O)=O)=O)=O)N)=O Chemical compound CCCCNC([C@H](CCCCNC(C(CO)NC(CNC(C(CO)NC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCOc(cc1)ccc1C(O)=O)=O)=O)=O)=O)=O)N)=O LOHODVKOTZCMNI-URRMOVRVSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167091 | 2012-05-08 | ||
| EP12167091.3 | 2012-05-08 | ||
| US201261646470P | 2012-05-14 | 2012-05-14 | |
| US61/646,470 | 2012-05-14 | ||
| US201261741770P | 2012-09-06 | 2012-09-06 | |
| US61/741,770 | 2012-09-06 | ||
| EP12183246.3 | 2012-09-06 | ||
| EP12183246 | 2012-09-06 | ||
| PCT/EP2013/059112 WO2013167454A1 (en) | 2012-05-08 | 2013-05-02 | Double-acylated glp-1 derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517477A JP2015517477A (ja) | 2015-06-22 |
| JP2015517477A5 true JP2015517477A5 (enExample) | 2016-06-09 |
| JP6250034B2 JP6250034B2 (ja) | 2017-12-20 |
Family
ID=49550172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510743A Active JP6250034B2 (ja) | 2012-05-08 | 2013-05-02 | 二重アシル化されたｇｌｐ−１誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10000542B2 (enExample) |
| EP (1) | EP2846823B1 (enExample) |
| JP (1) | JP6250034B2 (enExample) |
| CN (1) | CN104519902B (enExample) |
| WO (1) | WO2013167454A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| WO2013167455A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| WO2013167454A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| AP2015008781A0 (en) | 2013-05-28 | 2015-10-31 | Takeda Pharmaceutical | Peptide compound |
| AU2014283221A1 (en) | 2013-06-20 | 2015-12-03 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| CN105451776B (zh) * | 2013-08-15 | 2020-04-17 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| RU2016134425A (ru) | 2014-02-18 | 2018-03-20 | Ново Нордиск А/С | Стабильные аналоги глюкагона и их применение для лечения гипогликемии |
| EP3129041B1 (en) * | 2014-04-07 | 2019-06-12 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| US11572398B2 (en) | 2014-11-27 | 2023-02-07 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| CN107108714B (zh) | 2014-12-17 | 2022-02-08 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| TW201821434A (zh) | 2016-10-10 | 2018-06-16 | 法商賽諾菲公司 | 製備包含親脂性修飾的離胺酸側鏈的肽的方法 |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| CN120241968A (zh) | 2017-10-12 | 2025-07-04 | 诺和诺德股份有限公司 | 用于药物治疗的司美鲁肽 |
| LT3774862T (lt) * | 2018-04-05 | 2022-09-12 | Sun Pharmaceutical Industries Limited | Nauji glp-1 analogai |
| WO2019200594A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| US20230093542A1 (en) | 2020-02-18 | 2023-03-23 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| CN114729060B (zh) | 2020-09-30 | 2022-11-25 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| CN113461519A (zh) * | 2021-08-12 | 2021-10-01 | 浙江泽瑞生物医药有限公司 | 一种十八烷二酸单叔丁酯-pfp的制备方法 |
| CN116848243B (zh) | 2022-03-30 | 2024-03-19 | 北京质肽生物医药科技有限公司 | 多肽缀合物的液体药物组合物和其使用方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336782A (en) | 1991-04-24 | 1994-08-09 | Kuraray Co., Ltd. | Long chain carboxylic acid imide ester |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| WO1999043706A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| US6589503B1 (en) * | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| EP1932535A3 (en) | 1998-07-31 | 2008-10-29 | Novo Nordisk A/S | Stimulation of beta cell profileration |
| US20040121941A1 (en) * | 1999-09-28 | 2004-06-24 | Burm Brigitte Elisa Anna | Novel inhibitors of prenylated pyrophosphate consuming enzymes |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| CA2549582A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
| JP4933455B2 (ja) | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー／エス | 新規のインスリン誘導体 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| JP5606314B2 (ja) * | 2007-09-05 | 2014-10-15 | ノボ・ノルデイスク・エー／エス | Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途 |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| JP5411366B2 (ja) | 2009-12-16 | 2014-02-12 | ノヴォ ノルディスク アー／エス | 二重アシル化ｇｌｐ−１誘導体 |
| EP2637698B1 (en) * | 2010-11-09 | 2022-04-20 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| WO2013167455A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| WO2013167454A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
-
2013
- 2013-05-02 WO PCT/EP2013/059112 patent/WO2013167454A1/en not_active Ceased
- 2013-05-02 CN CN201380024302.6A patent/CN104519902B/zh active Active
- 2013-05-02 EP EP13721652.9A patent/EP2846823B1/en active Active
- 2013-05-02 JP JP2015510743A patent/JP6250034B2/ja active Active
- 2013-05-02 US US14/399,087 patent/US10000542B2/en active Active
-
2018
- 2018-04-30 US US15/966,642 patent/US10604554B2/en active Active
-
2019
- 2019-12-17 US US16/717,176 patent/US11518795B2/en active Active